Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
MaxCyte, Inc. - Common Stock
(NQ:
MXCT
)
1.220
+0.050 (+4.27%)
Streaming Delayed Price
Updated: 3:43 PM EDT, Jul 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MaxCyte, Inc. - Common Stock
< Previous
1
2
3
Next >
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
Today 8:05 EDT
Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
July 15, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
May 12, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
April 29, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 31, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
March 24, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
March 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
February 24, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
February 23, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results
January 12, 2026
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Planned CFO Transition in 2026
November 12, 2025
Company initiates search for successor
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 12, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
November 05, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
October 08, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
October 06, 2025
MaxCyte’s Flow Electroporation® Technology will support efficient gene delivery to advance Moonlight Bio’s engineered T cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
September 22, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance
August 06, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Platform License Agreement with Adicet Bio
August 04, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
July 31, 2025
MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
July 09, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
June 11, 2025
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance
May 07, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
April 10, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance
March 11, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
February 12, 2025
TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy program, for...
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
February 07, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
Glancy Prongay & Murray LLP Announces Investigation of MaxCyte, Inc. (MXCT)
January 30, 2025
From
Glancy Prongay & Murray LLP
Via
Business Wire
MaxCyte® Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments
January 30, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
January 13, 2025
From
MaxCyte, Inc
Via
GlobeNewswire
MaxCyte Announces Retirement of Board Member Art Mandell
December 23, 2024
From
MaxCyte, Inc
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
